文献速递乳腺癌放疗放疗物理与技术

左侧乳腺癌术后放疗侧卧位新技术的剂量学优势与临床可行性

Dosimetric advantages and clinical feasibility of a novel lateral decubitus position for left breast cancer patients undergoing PORT.
PubMed 文献 · Radiat Oncol · 2026-04-10

本研究提出一种新型侧卧位(nLDP)技术,用于无法维持深吸气屏气(DIBH)的左侧乳腺癌术后放疗患者。76例患者分三组比较,nLDP较仰卧自由呼吸显著降低心脏及亚结构剂量且不牺牲PTV覆盖,摆位误差小于0.5 cm,在低风险患者(FB-MHD<4 Gy)中nLDP心脏剂量降低程度与DIBH相当。

要点

  • nLDP显著降低全心脏及心脏亚结构平均剂量和V5 Gy–V30 Gy,不劣化PTV覆盖。
  • nLDP摆位误差小于0.5 cm,与仰卧位无显著差异。
  • FB-MHD<4 Gy患者中,nLDP心脏剂量降低与DIBH相当。

核心结论

  • nLDP为无法维持DIBH的左侧乳腺癌术后放疗患者提供有效的心脏保护替代方案,显著降低心脏剂量且不牺牲PTV覆盖和摆位稳定性。

研究设计与样本

  • 单中心研究,76例左侧乳腺癌术后放疗患者按体位和呼吸技术分为三组:Cohort 1(nLDP自由呼吸,n=28)、Cohort 2(仰卧自由呼吸,n=28)、Cohort 3(仰卧DIBH,n=20)。
  • 所有计划采用6 MV光子调强放疗(IMRT),PTV包括全乳/胸壁±区域淋巴结,评估剂量学参数、正常组织并发症概率(NTCP)、心脏-PTV解剖距离和摆位误差。
  • Cohort 1额外生成包含内乳淋巴结照射(IMNI)的计划进行剂量学比较,所有患者临床治疗均未行IMNI。

主要发现

  • Cohort 1中,无论是否包含IMNI,nLDP较仰卧位显著降低全心脏及心脏亚结构的平均剂量和V5 Gy–V30 Gy,且不 compromise PTV覆盖。
  • nLDP显著增加心脏-PTV距离,并降低心脏死亡和對侧乳腺第二原发恶性肿瘤的NTCP。
  • nLDP摆位误差保持在0.5 cm以下,与仰卧位相比无显著差异。
  • 在FB-MHD<4 Gy的患者中,nLDP实现的心脏剂量降低与DIBH相当。

关键数值与推荐

  • 低风险患者定义为自由呼吸平均心脏剂量(FB-MHD)<4 Gy。
  • nLDP摆位误差小于0.5 cm。
  • Cohort 1中75%接受改良根治术(MRM),中位年龄51.5岁;Cohort 2中61%接受MRM,中位年龄50.5岁;Cohort 3中55%接受MRM,中位年龄45岁。

临床怎么用

  • 对于无法维持DIBH的左侧乳腺癌术后放疗患者,可考虑采用nLDP以降低心脏剂量。
  • nLDP摆位稳定性与仰卧位相当,摆位误差小于0.5 cm,临床可行。
  • 在低风险患者(FB-MHD<4 Gy)中,nLDP可达到与DIBH相当的心脏保护效果。

局限性

  • 研究为单中心设计,样本量有限(共76例,Cohort 3仅20例)。
  • 所有患者临床治疗未行IMNI,IMNI相关比较仅基于Cohort 1的补充计划。
  • 未报告长期临床心脏结局,仅评估剂量学参数和NTCP。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation-induced cardiac toxicity remains a significant concern in breast cancer radiotherapy. Our institution developed a novel lateral decubitus position (nLDP) technique for patients unable to maintain deep inspiration breath-hold (DIBH) during postoperative radiotherapy (PORT). This study quantitatively evaluated the cardiac dosimetry benefits and setup errors of nLDP and compared its heart-sparing effects to DIBH within the low-risk patients (free breathing mean heart dose [FB–MHD] <4 Gy). METHODS: Patients with left-sided breast cancer indicated for PORT were enrolled and stratified into three cohorts based on positioning and breathing techniques: Cohort 1 (nLDP in FB, nLDP-FB), Cohort 2 (supine position in FB, SP-FB), and Cohort 3 (SP in DIBH, SP-DIBH). The planning target volume (PTV) encompassed the whole breast/chest wall ± regional lymph nodes, and organs at risk (OARs) were delineated according to institutional protocols. While all patients were clinically treated without internal mammary node irradiation (IMNI), supplementary IMN-inclusive plans were generated specifically for Cohort 1 for dosimetric comparison. All plans utilized 6 MV photon intensity-modulated radiation therapy (IMRT). Dosimetric parameters, normal tissue complication probability (NTCP), anatomical heart-PTV distances, and setup errors were assessed. For the low-risk patients, cardiac dose reductions in nLDP were compared with DIBH. RESULTS: A total of 76 patients were analyzed: Cohort 1 (n = 28, median age 51.5 years, 75% underwent modified radical mastectomy [MRM]), Cohort 2 (n = 28, median age 50.5 years, 61% MRM), and Cohort 3 (n = 20, median age 45 years, 55% MRM). In Cohort 1, nLDP significantly reduced the mean doses and V5 Gy–V30 Gy to the whole heart and cardiac substructures compared to SP, regardless of IMNI inclusion, without compromising PTV coverage. Furthermore, nLDP significantly increased the heart–PTV distance and lowered the NTCP for cardiac mortality and contralateral breast secondary malignancy. The setup errors for nLDP remained below 0.5 cm, with no significant difference compared to SP. In patients with FB-MHD < 4 Gy, nLDP achieved heart dose reductions comparable to DIBH. CONCLUSIONS: The nLDP offers an effective cardioprotective alternative to DIBH by significantly reducing cardiac doses without compromising PTV coverage and setup stability.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou Y, Xu J, Deng Y, et al. Dosimetric advantages and clinical feasibility of a novel lateral decubitus position for left breast cancer patients undergoing PORT. Radiat Oncol. 2026. PMID: 41964068. doi:10.1186/s13014-026-02836-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。